<DOC>
	<DOCNO>NCT00547196</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy without total-body irradiation donor umbilical cord blood transplant help stop growth cancer abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . When stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This clinical trial study well four different chemotherapy regimen give without total-body irradiation umbilical cord blood transplant work treat patient relapsed refractory hematologic cancer .</brief_summary>
	<brief_title>Study Four Different Chemotherapy Regimens With Without Total-Body Irradiation Followed Umbilical Cord Blood Transplant Treating Patients With Relapsed Refractory Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine survival day 100 patient relapse , refractory , poor-risk hematological malignancy treat four different preparative regimen follow allogeneic hematopoietic stem cell transplantation ( HSCT ) use two unrelated umbilical cord blood ( UCB ) unit . Secondary - To determine incidence time neutrophil engraftment patient treat regimen . - To determine incidence time platelet engraftment patient treat regimen . - To determine incidence severity acute chronic graft-versus-host-disease ( GVHD ) patient treat regimen . - To determine survival day 180 patient treated regimen . - To determine disease-free survival patient treat regimen . - To determine incidence primary secondary engraftment failure patient treat regimen . - To determine incidence transplantation-related complication ( e.g. , infection , veno-occlusive disease liver , organ toxicity ) patient . - To determine incidence post-transplantation-related lymphoproliferative disease , secondary myelodysplastic syndrome , secondary malignancy patient . - To determine incidence relapse patient treat regimen . - To determine post-transplantation chimerism patient treat regimen . - To determine immune reconstitution patient treat regimen . OUTLINE : This multicenter study . - Preparative regimen : Patients assign 1 4 preparative regimen . - Regimen 1 ( patient &lt; 50 year age contraindication fractionate total-body irradiation ( FTBI ) : Patients undergo FTBI 2-3 time day day -9 -6 total 11 fraction . Patients also receive cyclophosphamide IV 2 hour day -5 -4 fludarabine phosphate IV day -5 -2 . - Regimen 2 ( patient &lt; 50 year age unable tolerate FTBI due prior dose-limiting radiotherapy significant cardiotoxicity ) : Patients receive test dose busulfan day -10 dose adjust busulfan IV 3-4 time daily day -9 -6 , melphalan IV day -5 -4 , fludarabine phosphate IV day -5 -2 . - Regimen 3* ( patient unable tolerate regimen 1 2 ; age exclusion ) : Patients receive fludarabine phosphate IV day -8 -4 cyclophosphamide IV 2 hour day -3 undergo TBI ( single dose ) day -2 . - Regimen 4* ( patient unable tolerate regimen 1 2 ) : Patients receive fludarabine phosphate IV day -7 -3 melphalan IV day -2 . NOTE : *Treating physician decide choice regimen 3 4 - Umbilical cord blood ( UCB ) transplantation : Patients receive 2 combine unit UCB IV day 0 . Patients also receive G-CSF IV subcutaneously begin day 5 ( later ) continue blood count recover . - Graft-versus-host-disease prophylaxis : Patients receive cyclosporine IV twice daily begin day -1 follow taper accord institutional guideline . Patients also receive mycophenolate mofetil orally IV begin day 0 continue day 27 ( clinically indicate ) . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hematological lymphatic malignancy , include follow : Acute myeloid leukemia Relapsed primary refractory disease &lt; 10 % blast peripheral blood smear In first remission poor risk factor molecular prognosis [ i.e. , AML 5 , 7 , ( 6 ; 9 ) , tri8 , 11 ] ( preparative regimen 3 4 ) Acute lymphocytic leukemia In second complete remission higher OR first remission poor risk factor , include follow ( preparative regimen 1 2 ) : BCR/ABL fluorescence situ hybridization ( FISH ) reverse transcriptasepolymerase chain reaction ( 9 ; 22 ) ( q34 ; q11 ) detect cytogenetics Chromosomes &lt; 44 cytogenetics DNA index &lt; 0.81 flow cytometry Any rearrangement chromosome 11 result disruption MLL gene ( 11q23 ) cytogenetics SER In first remission poor risk factor molecular prognosis [ ALL Philadelphia chromosomepositive ( 9 ; 22 ) , ( 4 ; 22 ) , ( q34 ; q11 ) ] ( preparative regimen 3 4 ) Chronic myelogenous leukemia In accelerated phase great ( preparative regimen 1 2 ) In accelerated second chronic phase ( preparative regimen 3 4 ) Myelodysplastic syndrome With deletion chromosome 7 short arm chromosome 5 ( preparative regimen 1 2 ) In high highintermediate risk category ( preparative regimen 3 4 ) NonHodgkin lymphoma relapse marrow involvement Refractory chronic lymphocytic leukemia Patients deem ineligible conventional highdose chemotherapy program ( i.e. , regimens 1 2 ) due follow concurrent medical condition may eligible regimen 3 4 discretion treat physician principal investigator ( preparative regimen 3 4 ) : LVEF &lt; 50 % &gt; 40 % FEV1 , FVC , DLCO &lt; 50 % Bilirubin &gt; 3 mg/dL Creatinine &gt; 2 mg/dL Two partially HLAmatched umbilical cord blood ( UCB ) unit available HLAmatched minimally 4 6 HLAA , HLAB , DRB1 locus patient DRB1 match high resolution DNA type HLAA HLAB match low resolution `` serological match '' level Two pool unit nucleate cell number &gt; 2.5 x 10^7/kg No available HLAidentical sibling 1 antigenmismatched relate donor No available HLAmatched unrelated bone marrow donor PATIENT CHARACTERISTICS : See Disease Characteristics Karnofsky performance status ( PS ) 60100 % OR Lansky PS 60100 % OR Zubrod PS 01 Physiological age 60 le ( chronological age ) Weight &gt; 50 kg Creatinine normal age OR creatinine clearance 24hour urine collection glomerular filtration rate &gt; 60 mL/min Bilirubin ≤ 1.5 mg/dL LVEF ≥ 50 % DLCO ≥ 60 % predict No HIV1 infection No active uncontrolled infection Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Recovered prior intensive chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>